Thematic Investing: AI Applications in Healthcare - Patient Monitoring Deep Dive
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Barclays presents a comprehensive chartbook exploring the integration of artificial intelligence within patient monitoring, identifying it as a critical healthcare application bolstered by expanding datasets, evolving business models, and shifting care delivery paradigms. The report identifies over 45 relevant public and private companies, spanning established medical device manufacturers like Boston Scientific, GE HealthCare, and Philips, alongside major technology firms including Apple, Samsung Electronics, and Nordic Semiconductor.
The integration of AI promises transformative clinical advantages, such as early disease detection, personalized chronic disease management, and predictive alert systems. These innovations are increasingly vital given persistent healthcare labor shortages, which necessitate remote care capabilities to maximize inpatient capacity and minimize readmission rates. While acknowledging ongoing challenges related to data interoperability, cybersecurity, and privacy, the bank notes that acceptance among both patients and healthcare providers is rapidly accelerating. IQVIA projects that remote patient monitoring solutions will cover 40% of the US population by 2030.
Currently, the most mature commercial applications include cardiac monitoring, continuous glucose monitoring, and connected care solutions, many of which have already secured necessary regulatory clearances. Future growth opportunities are expected to expand into clinical trial enablement, pharmacovigilance, maternal-fetal monitoring, and connected eldercare. Prominent venture capital deployments, including $150 million for Cera and $100 million for VitalConnect, further validate the sector's commercial momentum. While the thematic landscape also features early-stage wildcard concepts like digital twins and dynamic health insurance pricing, established medical device and tech companies remain the primary avenues for thematic exposure.